McKesson on Monday named Brad Lerman a new independent director, effective April 24, 2018. With the election of Lerman, the size of McKesson’s board of directors increases from eight to nine members, eight of whom are independent. Lerman, age 61, is senior vice president, general counsel and corporate secretary for Medtronic.
“With more than 25 years of experience bringing insights that bridge compliance and government relations with corporate strategy, Brad will be an immediate asset to McKesson’s board of directors,” John Hammergren, chairman and chief executive officer of the San Francisco-based wholesaler, said. “His deep understanding of the healthcare industry and experience in the public and private sectors bring valuable insights to our board. We have an ongoing commitment to regularly refreshing and strengthening our board, and Brad is a perfect match for the background we were seeking in this search process.”
Lerman leads the company’s global legal, government affairs and ethics and compliance functions. Prior to Medtronic, Brad served as executive vice president, general counsel and corporate secretary for the Federal National Mortgage Association (Fannie Mae) and as senior vice president, associate general counsel and chief litigation counsel for Pfizer.
For a decade, Lerman served as a private practice attorney and litigation partner at Winston & Strawn in Chicago. Prior to private practice, he served as a federal prosecutor for the U.S. Department of Justice, where he was an assistant U.S. attorney in the Northern District of Illinois for eight years.